Genentech Alzheimer's drug misses goals in studies - KWES NewsWest 9 / Midland, Odessa, Big Spring, TX: newswest9.com |

Genentech Alzheimer's drug misses goals in studies

Posted: Updated:
  • NationalMore>>

  • Rare storm at California beach hard to see coming

    Rare storm at California beach hard to see coming

    Monday, July 28 2014 9:55 PM EDT2014-07-29 01:55:00 GMT
    A 20-year-old man died after lightning from a rare summer thunderstorm jolted a Southern California beach, injuring or rattling more than a dozen people, authorities said.
    A thunderstorm formed so rapidly over a Southern California beach that experts said Monday it was impossible for anyone to predict a lightning strike would turn a day of carefree fun into one of terror.
  • Judge OKs record-setting $2B sale of Clippers

    Judge OKs record-setting $2B sale of Clippers

    Monday, July 28 2014 9:39 PM EDT2014-07-29 01:39:08 GMT
    Only final arguments and a ruling remain in the trial to determine whether Donald Sterling's estranged wife can sell the Los Angeles Clippers to former Microsoft CEO Steve Ballmer for $2 billion.
    Embattled Los Angeles Clippers owner Donald Sterling lost his attempt to block the $2 billion sale of the team to former Microsoft CEO Steve Ballmer.
  • FBI defends search for Oklahoma City bombing video

    FBI defends search for Oklahoma City bombing video

    Monday, July 28 2014 9:26 PM EDT2014-07-29 01:26:10 GMT
    A Salt Lake City attorney is arguing in a lawsuit that the FBI has video of the Oklahoma City bombing that shows a second person was involved.
    The FBI thoroughly searched its archives and found no evidence that more videos of the Oklahoma City bombing exist, agency employees told a judge Monday in a trial that has rekindled questions about whether any others were...
By MARILYNN MARCHIONE
AP Chief Medical Writer

An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.

Pneumonia and deaths were more common among those receiving the drug, but researchers downplayed that. Study leader Dr. Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people.

"We're very encouraged" by the hint of benefit for patients with milder dementia and will talk with regulators about next steps for the drug, crenezumab (cruh-NEZ-oo-mab), said a Genentech scientist, Dr. Carole Ho. The results fit with other evidence suggesting that treating earlier in the course of the disease is better, she said.

Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.

They are the latest mixed bag on treatments aimed at clearing away the sticky amyloid plaques clogging Alzheimer's patients' brains. About 35 million people worldwide have Alzheimer's, the most common form of dementia. There is no cure and current treatments only temporarily ease symptoms.

Last year, an Eli Lilly & Co. medicine, solanezumab, that also sought to clear away amyloid missed main goals in two studies but combined results suggested it might help people with milder disease. It's in further study now. Before that, bapineuzumab, a similar drug being developed by Pfizer Inc. and Johnson & Johnson, showed promise in mid-stage testing but flopped in larger, more definitive trials.

The Genentech drug has been closely watched because it targets amyloid more broadly than the other drugs do, and the California-based company has a long track record of success with many biological medicines against cancer.

Mid-stage studies aim to give some idea of safety and whether the drug is effective enough to advance to larger, more definitive studies aimed at winning market approval.

In one study, 431 patients ages 50 to 80 with mild to moderate Alzheimer's were given crenezumab or dummy drug as shots every two weeks, or as a higher dose in infusions every four weeks for 17 months. No significant difference was seen among the groups on two widely used measures of thinking and functioning skills.

However, the 70 most mildly impaired participants who received the higher dose declined 35 percent less on the cognitive measure than the 33 mildly impaired people given dummy infusions. The difference was about 3.5 points on the roughly 70-point scale - "equivalent to six or nine months" of delay in decline, Cummings said.

This result isn't definitive, though, and can only be considered a signal worth exploring in future research because it didn't involve the whole group tested. And even in this mildly impaired group, the drug did not improve the second measure, ability to function in daily life.

In the second study, 73 people who showed amyloid plaques on brain imaging also were given crenezumab or dummy shots or infusions. The main outcome - levels of amyloid seen on brain imaging after treatment - will be presented at a medical conference in November. Results on cognitive function seem to mirror those in the larger study, Cummings said.

Five people given crenezumab died - one from sudden death, two from respiratory failure, one from pneumonia and one from worsening Alzheimer's.

"We believe that the safety profile is acceptable," because deaths do not seem related to the drug, Genentech's Ho said. "It is not a show stopper."

Genentech and its corporate parent, Switzerland-based Roche Holding AG, paid for the study and Cummings is a paid adviser to Genentech.

In a statement Wednesday, the Alzheimer's Association noted that crenezumab was being tested in another study aimed at preventing the disease, and said the new results give hope it will be more successful in that setting.

___

Online:

National Institute on Aging: http://www.nia.nih.gov/Alzheimers

Patient, family info: http://www.alzheimers.gov/

Alzheimer's Association: http://www.alz.org

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

  • InternationalMore>>

  • Israel target symbols of Hamas control in Gaza

    Israel target symbols of Hamas control in Gaza

    Tuesday, July 29 2014 12:38 AM EDT2014-07-29 04:38:03 GMT
    Israeli aircraft, tanks and navy gunboats pounded symbols of Hamas control in Gaza City in the heaviest night of bombardment in three weeks of Israel-Hamas fighting.
    Israeli aircraft, tanks and navy gunboats pounded symbols of Hamas control in Gaza City in the heaviest night of bombardment in three weeks of Israel-Hamas fighting.
  • New fears about Ebola spread after plane scare

    New fears about Ebola spread after plane scare

    Monday, July 28 2014 11:01 PM EDT2014-07-29 03:01:05 GMT
    No one knows for sure just how many people Patrick Sawyer came into contact with the day he boarded a plane in Liberia, had a layover in Togo and then arrived in Nigeria where authorities say he died days later...
    No one knows for sure just how many people Patrick Sawyer came into contact with the day he boarded a flight in Liberia, had a stopover in Ghana, changed planes in Togo, and then arrived in Nigeria, where authorities say...
  • Be ready for 'prolonged' Gaza war, Netanyahu says

    Be ready for 'prolonged' Gaza war, Netanyahu says

    Monday, July 28 2014 10:30 PM EDT2014-07-29 02:30:02 GMT
    Israel and Hamas have lowered the pace of the fighting in the three-week-old Gaza war as international efforts intensify to end the conflict that has already killed 1,030 Palestinians and 43 Israeli soldiers.
    Signaling an escalation of Israel's Gaza operation, Prime Minister Benjamin Netanyahu told Israelis Monday to be ready for a "prolonged" war, and the military warned Palestinians in three large neighborhoods to leave...